Abstract 831P
Background
Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe RCC (mchRCC), is limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients, in terms of outcome and comparison to mccRCC.
Methods
Records from mchRCC patients treated with first line sunitinb in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC pts were individually matched to mccRCC pts. We compared the clinical benefit rate (CBR), progression free survival (PFS), and overall survival (OS) between the groups.
Results
Between 2004-2014, 36 patients (median age 64, 47% male) with mchRCC were treated with first line sunitinib. 78% achieved a clinical benefit (partial response + stable disease). Median progression free survival (PFS) and overall survival (OS) were 10 and 26 months, respectively. Factors associated with PFS were the HENG risk (HR 3.3, p = 0.03) and pre-treatment neutrophil to lymphocyte ratio (NLR) >3 (HR 0.63, p = 0.02). Factors associated with OS were the HENG risk (HR 4.1, p = 0.04), liver metastases (HR 3.8, p = 0.03), and pre-treatment NLR
Conclusions
In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The HENG risk and pre-treatment NLR may be associated with PFS and OS.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
N/A
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Utility of algorithm-based chemoradioselection for advanced laryngeal and hypopharyngeal carcinoma
Presenter: Muneyuki Masuda
Session: Poster display
Resources:
Abstract
Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting
Presenter: Tera Eerkes
Session: Poster display
Resources:
Abstract
Uterine carcinosarcoma: a retrospective clinical cohort analysis
Presenter: Carla Perna
Session: Poster Display
Resources:
Abstract
Using mouse and human pancreatic organoids to infer resistance to targeted therapy
Presenter: Mariano Ponz-Sarvise
Session: Poster display
Resources:
Abstract
Using diffusion-weighted MRI derived apparent diffusion coefficient as a predictive biomarker of tumor response in non-Hodgkin lymphoma
Presenter: Siarhei Kharuzhyk
Session: Poster display
Resources:
Abstract
Use of treatments of questionable benefit in hospitalized patients with metastatic gastric or esophageal cancer near the end of life. A country-wide, register-based study
Presenter: Emmanuelle Kempf
Session: Poster display
Resources:
Abstract
Use of Oncotype DX Recurrence Score® (RS) reduces chemotherapy (CT) beyond treatment decisions using Ki67-based determinations of luminal A and B breast cancer subtypes: a retrospective study in the Spanish population
Presenter: Laura Garcia-Estevez
Session: Poster display
Resources:
Abstract
Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study
Presenter: Petra Pichler
Session: Poster display
Resources:
Abstract
Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC). Part1: the ENCOURAGE cohort of 1158 patients (pts) by GINECO
Presenter: Dominique Berton-Rigaud
Session: Poster Display
Resources:
Abstract
Use and clinical impact of conventional cytotoxic chemotherapy (CTx) subsequent to immunotherapy in metastatic melanoma
Presenter: Eoghan Malone
Session: Poster display
Resources:
Abstract